Achieve life sciences reports q4 loss per share of $0.30

Achieve reports financial results for fourth quarter and year-end 2019 and provides update on cytisinicline development program.achieve life sciences - as of dec 31, 2019, co's cash, cash equivalents, and restricted cash was $16.7 million.achieve life sciences qtrly loss per share $0.30.q4 earnings per share view $-0.32 -- refinitiv ibes data.
ACHV Ratings Summary
ACHV Quant Ranking